VEGF in Ovarian Tumors and Patient Survival
Author Information
Author(s): S Yamamoto, I Konishi, M Mandal, H Kuroda, T Komatsu, K Nanbu, H Sakahara, T Mori
Primary Institution: Kyoto University
Hypothesis
Is there a correlation between VEGF expression in ovarian neoplasms and clinicopathological factors or patient survival?
Conclusion
Strong VEGF expression is associated with poorer survival rates in ovarian carcinoma patients.
Supporting Evidence
- 97% of ovarian carcinomas showed positive immunostaining for VEGF.
- Patients with strong VEGF staining had poorer survival rates than those with weak or no staining.
- Serum VEGF levels were significantly higher in carcinoma patients compared to those with benign tumors.
Takeaway
This study found that a protein called VEGF is found more in cancerous ovarian tumors than in benign ones, and higher levels of VEGF are linked to worse survival for patients.
Methodology
VEGF expression was analyzed immunohistochemically in 110 epithelial ovarian tumors, and serum VEGF levels were measured using enzyme immunoassay.
Limitations
The study may not account for all factors influencing VEGF levels and patient survival.
Participant Demographics
110 women who underwent laparotomy for ovarian tumors, including benign cystadenomas, LMP tumors, and carcinomas.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website